FindTrial
Sign In

Dosimetric Correlation of radiotherapy doses to neural stem cell in patients with newly diagnosed glioblastoma treated with conventional adjuvant therapy.

Dosimetric correlation of radiotherapy doses to neural stem cell niche areas with outcome data in patients with newly diagnosed glioblastoma treated with conventional adjuvant therapy. - SVZ study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/011809
Enrollment
100
Registered
2018-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G938- Other specified disorders of brain Health Condition 2: null- patients presenting to TMH with newly diagnosed glioblastoma have been taken for the study

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with newly diagnosed glioblastoma will be taken for the study.

Exclusion criteria

Exclusion criteria: treated cases of glioblastoma; poor KPS patients will be excluded from the studies;

Design outcomes

Primary

MeasureTime frame
Progression free survival and overall survival in relation to the radiotherapy doses to the ipsilateral, contralateral and bilateral SVZ.Timepoint: Progression free survival—

Secondary

MeasureTime frame
Correlation of pattern of failures with respect to radiotherapy doses received by SVZ and the spatial relation of the primary tumour with SVZ.Timepoint: overall survival—

Countries

India

Contacts

Public ContactDr Tejpal Gupta

tata memorial centre

tejpalgupta@rediffmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026